GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » Quick Ratio

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Quick Ratio : 7.56 (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. SciClone Pharmaceuticals's quick ratio for the quarter that ended in Jun. 2017 was 7.56.

SciClone Pharmaceuticals has a quick ratio of 7.56. It generally indicates good short-term financial strength.

The historical rank and industry rank for SciClone Pharmaceuticals's Quick Ratio or its related term are showing as below:

SCLN's Quick Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.34
* Ranked among companies with meaningful Quick Ratio only.

SciClone Pharmaceuticals Quick Ratio Historical Data

The historical data trend for SciClone Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals Quick Ratio Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.12 3.86 4.90 4.28 6.78

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.31 6.93 6.78 9.58 7.56

Competitive Comparison of SciClone Pharmaceuticals's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's Quick Ratio falls into.



SciClone Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

SciClone Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Quick Ratio (A: Dec. 2016 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(195.733-16.587)/26.441
=6.78

SciClone Pharmaceuticals's Quick Ratio for the quarter that ended in Jun. 2017 is calculated as

Quick Ratio (Q: Jun. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(231.008-22.039)/27.627
=7.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals  (NAS:SCLN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


SciClone Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480